Revvity, Inc. (0KHE.L)

109,83 +0,90 (+0,83 %) À la clôture : 06:16PM BST

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Secteur(s): 
Secteur d’activité: 
Employés à temps plein: 11 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Prahlad R. Singh Ph.D.	CEO, President & Director	1,43M	S.O.	1965
Mr. Maxwell Krakowiak	Senior VP & CFO	631,11k	S.O.	1990
Mr. Tajinder S. Vohra	Senior Vice President of Global Operations	574,08k	S.O.	1966
Mr. Joel S. Goldberg	Senior VP of Administration, General Counsel & Secretary	720,74k	S.O.	1969
Ms. Miriame Victor	Senior VP & Chief Commercial Officer	555,4k	S.O.	1982
Mr. Andrew Okun	VP, Chief Accounting Officer & Treasurer	S.O.	S.O.	1970
Ms. Madhuri Hegde FACMG, Ph.D.	Senior VP & Chief Scientific Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Revvity, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 10; Société : 3; Droits des actionnaires : 8; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.